ArticleMuscle & nerve2021
The cumulative incidence of dysphagia and dysphagia-free survival in persons diagnosed with amyotrophic lateral sclerosis.
Article in Muscle & nerve, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Dysphagia in Hospitalised Older Adults: Prevalence, Incidence and Predictors in the Multicentre NUTRIFAG Cohort: Empirical Research Quantitative.Nursing open · 2026Observational
- Unrevealing the sequence of dysphagia progression in ALS: an event-based, FEES-driven staging approach.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Factors Influencing Decision Making for Gastrostomy Tube Placement for People Living with Serious Illness: A Scoping Review.Journal of palliative medicine · 2025Article
- Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis.Journal of neurology · 2024Review
- Manual Therapy of Dysphagia in a Patient with Amyotrophic Lateral Sclerosis: A Case Report.Medicina (Kaunas, Lithuania) · 2024Article
- Supporting people with Motor Neuron Disease (MND) to make decisions about gastrostomy feeding tube placement: a survey of UK healthcare professionals' practice and beliefs.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2024Article
- The Current State and Future Directions of Swallowing Care in Amyotrophic Lateral Sclerosis.Current physical medicine and rehabilitation reports · 2023Article
- Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study.Frontiers in neurology · 2023Article
- Predicting dysphagia onset in patients with ALS: the ALS dysphagia risk score.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2022Article
- Esophageal Speech for a Patient with Amyotrophic Lateral Sclerosis Who Underwent a Central-part Laryngectomy to Prevent Aspiration: A Case Report.Progress in rehabilitation medicine · 2022Article
- Individualized predictions for clinical milestone in amyotrophic lateral sclerosis: A multialgorithmic approach.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
INTRODUCTION/
aimsDysphagia worsens mortality and quality of life for persons diagnosed with amyotrophic lateral sclerosis (ALS), yet our understanding of its incidence and timing remains limited. In this study we sought to estimate dysphagia incidence and dysphagia-free survival over time.
methodsUsing data from the Pooled Resource Open-Access ALS Clinical Trials Database, we compared characteristics of persons with and without dysphagia upon study entry. To account for competing mortality risk, we used Kaplan-Meier curves to estimate the cumulative incidence of dysphagia and the median number of days until the development of dysphagia or death in those without dysphagia at study entry.
resultsPatients with dysphagia upon study entry were more likely to have bulbar onset and had faster rates of functional decline and shorter diagnostic delays. The cumulative incidence of new-onset dysphagia was 44% at 1 year and 64% at 2 years after trial enrollment for those with spinal onset, and 85% and 92% for those with bulbar onset. The median duration of dysphagia-free survival after trial enrollment was 11.5 months for those with spinal onset and 3.2 months for those with bulbar onset. DISCUSSION: Our findings underscore the high risk for dysphagia development and support the need for early dysphagia referral and evaluation to minimize the risk of serious dysphagia-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.